Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
ACS Nano ; 17(13): 12358-12373, 2023 07 11.
Artículo en Inglés | MEDLINE | ID: mdl-37358244

RESUMEN

Herein, we have developed nanohybrids (nHs) to remotely activate a therapeutic enzyme for its use in Directed Enzyme Prodrug Therapy (DEPT). The coencapsulation of magnetic nanoparticles (MNPs) with horseradish peroxidase (HRP) using biomimetic silica as an entrapment matrix was optimized to obtain nanosized hybrids (∼150 nm) for remote activation of the therapeutic enzyme. HRP converts indole-3-acetic acid (3IAA) into peroxylated radicals, whereas MNPs respond to alternating magnetic fields (AMFs) becoming local hotspots. The AMF application triggered an increase in the bioconversion rate of HRP matching the activity displayed at the optimal temperature of the nHs (Topt = 50 °C) without altering the temperature of the reaction media. This showed that enzyme nanoactuation is possible with MNPs even if they are not covalently bound. After an extensive physicochemical/magnetic characterization, the spatial location of each component of the nH was deciphered, and an insulating role of the silica matrix was suggested as critical for introducing remote control over HRP. In vitro assays, using a human pancreatic cancer cell line (MIA PaCa-2), showed that only upon exposure to AMF and in the presence of the prodrug, the enzyme-loaded nHs triggered cell death. Moreover, in vivo experiments showed higher reductions in the tumor volume growth in those animals treated with nHs in the presence of 3IAA when exposed to AMF. Thus, this work demonstrates the feasibility of developing a spatiotemporally controlled DEPT strategy to overcome unwanted off-target effects.


Asunto(s)
Nanopartículas , Neoplasias , Profármacos , Animales , Humanos , Profármacos/farmacología , Profármacos/uso terapéutico , Calefacción , Dióxido de Silicio , Fenómenos Magnéticos , Campos Magnéticos , Neoplasias/tratamiento farmacológico
2.
Nanomedicine (Lond) ; 14(18): 2409-2422, 2019 09.
Artículo en Inglés | MEDLINE | ID: mdl-31456488

RESUMEN

Aim: To determine whether a p38 MAPK inhibitor incorporated into nanoemulsion-based chitosan nanocapsules can reduce the activity of this kinase in the brain through their nasal administration in mice. Materials & methods: We selected the p38 MAPK inhibitor PH797804, an ATP-competitive inhibitor of p38α encapsulated in nanoemulsion-based chitosan nanocapsules. Biological effect was evaluated in microglial and neuronal cells in vitro and in ex vivo and in vivo systems, in a mouse model of Alzheimer's disease. Results: Encapsulated inhibitor retains enzymatic inhibitory activity and tissue penetration capacity in vitro, ex vivo and in vivo. Conclusion: Nasal administration of chitosan nanocapsules can be an effective approach for brain-restricted reduction of p38 MAPK activity, thus reducing the side effects of systemic administration.


Asunto(s)
Benzamidas/administración & dosificación , Encéfalo/efectos de los fármacos , Quitosano/química , Nanocápsulas/química , Inhibidores de Proteínas Quinasas/administración & dosificación , Piridonas/administración & dosificación , Proteínas Quinasas p38 Activadas por Mitógenos/antagonistas & inhibidores , Administración Intranasal , Enfermedad de Alzheimer/tratamiento farmacológico , Enfermedad de Alzheimer/metabolismo , Animales , Benzamidas/farmacocinética , Benzamidas/uso terapéutico , Encéfalo/metabolismo , Línea Celular , Modelos Animales de Enfermedad , Sistemas de Liberación de Medicamentos , Femenino , Masculino , Ratones , Inhibidores de Proteínas Quinasas/farmacocinética , Inhibidores de Proteínas Quinasas/uso terapéutico , Piridonas/farmacocinética , Piridonas/uso terapéutico , Ratas Wistar , Proteínas Quinasas p38 Activadas por Mitógenos/metabolismo
3.
Mar Drugs ; 14(10)2016 Sep 30.
Artículo en Inglés | MEDLINE | ID: mdl-27706041

RESUMEN

The tunability of the properties of chitosan-based carriers opens new ways for the application of drugs with low water-stability or high adverse effects. In this work, the combination of a nanoemulsion with a chitosan hydrogel coating and the following poly (ethylene glycol) (PEG) grafting is proven to be a promising strategy to obtain a flexible and versatile nanocarrier with an improved stability. Thanks to chitosan amino groups, a new easy and reproducible method to obtain nanocapsule grafting with PEG has been developed in this work, allowing a very good control and tunability of the properties of nanocapsule surface. Two different PEG densities of coverage are studied and the nanocapsule systems obtained are characterized at all steps of the optimization in terms of diameter, Z potential and surface charge (amino group analysis). Results obtained are compatible with a conformation of PEG molecules laying adsorbed on nanoparticle surface after covalent linking through their amino terminal moiety. An improvement in nanocapsule stability in physiological medium is observed with the highest PEG coverage density obtained. Cytotoxicity tests also demonstrate that grafting with PEG is an effective strategy to modulate the cytotoxicity of developed nanocapsules. Such results indicate the suitability of chitosan as protective coating for future studies oriented toward drug delivery.


Asunto(s)
Quitosano/química , Quitosano/toxicidad , Nanocápsulas/química , Nanocápsulas/toxicidad , Animales , Supervivencia Celular/efectos de los fármacos , Chlorocebus aethiops , Portadores de Fármacos/química , Portadores de Fármacos/toxicidad , Sistemas de Liberación de Medicamentos , Estabilidad de Medicamentos , Técnicas Electroquímicas , Emulsiones , Concentración de Iones de Hidrógeno , Tamaño de la Partícula , Polietilenglicoles/química , Propiedades de Superficie , Termogravimetría , Células Vero
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA